Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) declared today that the U.S. Food and Tablets Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets all for the treatment of Clostridium difficile-associated diarrhoea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among group previously at poor risk for the disease. In the largest Phase 3 clinical studies ever conducted within CDAD, DIFICID had clinical response rates at the failure of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.

To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/

The December 15 issue of the journal Nature includes signal “Outlook” section focusing next to twofold myeloma. According to the National Cancer Institute, multiple myeloma or plasma cell myeloma is the second record common blood cancer within the United States accounting … Continue reading →


  1. Courtny Gerrish reports